期刊论文详细信息
Cancers
Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
Meena Jhanwar-Uniyal1  Michael Labagnara2  Marissa Friedman2  Amanda Kwasnicki2  Raj Murali2 
[1] Department of Neurosurgery, New York Medical College, Valhalla, NY 10595, USA;
关键词: brain tumors;    GBM;    cancer stem cells;    mTOR;    therapies;   
DOI  :  10.3390/cancers7020538
来源: mdpi
PDF
【 摘 要 】

Glioblastoma (GBM), a WHO-defined Grade IV astrocytoma, is the most common and aggressive CNS malignancy. Despite current treatment modalities, the survival time remains dismal. The main cause of mortality in patients with this disease is reoccurrence of the malignancy, which is attributed to treatment-resistant cancer stem cells within and surrounding the primary tumor. Inclusion of novel therapies, such as immuno- and DNA-based therapy, may provide better means of treating GBM. Furthermore, manipulation of recently discovered non-coding microRNAs, some of which regulate tumor growth through the development and maintenance of GBM stem cells, could provide new prospective therapies. Studies conducted by The Cancer Genome Atlas (TCGA) also demonstrate the role of molecular pathways, specifically the activated PI3K/AKT/mTOR pathway, in GBM tumorigenesis. Inhibition of the aforementioned pathway may provide a more direct and targeted method to GBM treatment. The combination of these treatment modalities may provide an innovative therapeutic approach for the management of GBM.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.

【 预 览 】
附件列表
Files Size Format View
RO202003190014998ZK.pdf 720KB PDF download
  文献评价指标  
  下载次数:14次 浏览次数:27次